Silo Pharma Completed Pre-investigational New Drug Meeting With FDA For SPC-15, An Intranasal Prophylactic Treatment For Post-traumatic Stress Disorder And Stress-induced Anxiety Disorder
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has completed a pre-IND meeting with the FDA for SPC-15, an intranasal treatment for PTSD and stress-induced anxiety. The meeting focused on aligning with the FDA on the 505(b)(2) regulatory pathway, which could expedite approval and reduce costs.
September 10, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's pre-IND meeting with the FDA for SPC-15 could expedite the drug's approval process and reduce development costs, potentially benefiting the company's stock.
The successful pre-IND meeting with the FDA indicates progress in Silo Pharma's drug development process. The 505(b)(2) pathway can lead to faster approval and lower costs, which is positive for the company's financial outlook and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100